(redirected from cutaneous amyloidosis)
Also found in: Dictionary, Thesaurus, Medical.
Related to cutaneous amyloidosis: macular amyloidosis


Deposition of amyloid in one or more organs of the body.



or amyloid dystrophy, a disorder of protein metabolism accompanied by the formation within tissues of a specific protein polysaccharide complex known as amyloid. The progress of the disease is associated with distortion of the protein-synthesizing function of the reticuloendothelial system and with accumulation of anomalous proteins in the blood plasma which act as autoantigens and also stimulate the formation of autoantibodies. As a result of antigen-antibody interaction, there is deposition of widely dispersed proteins which figure in the formation of amyloid. Once deposited in tissues, such as vascular and gland walls, the amyloid displaces functionally specialized elements of the organ; this process leads to the destruction of the organ.

Several types of amyloidosis are recognized: primary, secondary, and senile amyloidosis; amyloidosis with multiple myeloma; and localized tumorlike amyloidosis. Primary amyloidosis has no connection with any other disease; it affects mainly the cardiovascular system, alimentary tract, muscles, and skin. Secondary amyloidosis develops subsequent to other diseases which are accompanied by prolonged suppuration and tissue breakdown, such as tuberculosis, syphilis, and rheumatoid arthritis. It most often affects the spleen, liver, kidneys, adrenal glands, and intestines. Senile amyloidosis usually involves the heart. Amyloidosis may be either general or localized. Im-munodepressive and hepatic preparations are used in its treatment.


References in periodicals archive ?
Presence of cutaneous amyloidosis should prompt blood sugar assessment.
Therefore, the presence of cutaneous amyloidosis should prompt one to investigate for associated conditions.
ACD is a rare distinct variant of primary cutaneous amyloidosis.
Even if there are several treatment alternatives for primary cutaneous amyloidosis, the results are unsatisfactory and since the disease runs a chronic course, therapeutic management remains challenging.
A study of secondary cutaneous amyloidosis in basal cell carcinoma in Chinese patients: lack of correlation with bcl-2 or p53 protein expression.
In general, the treatment of cutaneous amyloidosis is disappointing.
Macular amyloidosis (MA) is the most subtle of the cutaneous amyloidosis.